Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

More articles from In vitro and In vivo Oncology

  • You have access
    An optimizer for patient-specific therapy with radiopharmaceutical cocktails
    Sumudu Katugampola, Jianchao Wang and Roger Howell
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4051;
  • You have access
    Preclinical evaluation of 67Cu-PSMA-617 theranostic as an alternative to 177Lu-PSMA-617 for prostate cancer
    Anand Nambisan, Musharraf Khan, Hanan Babeker, Jessica Pougoue Ketchemen, Anjong Tikum, Sharayu Karkare, Fabrice Ngoh Njotu and Humphrey Fonge
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4024;
  • You have access
    In Vitro Evaluation of PSMA Expression Levels Following External Beam Irradiation – Is There Any Potential to Modulate the Efficacy of PSMA-Targeting Prostate Cancer Therapy?
    Daria Arbuznikova, Melanie Boll, Anca-Ligia Grosu, Philipp Meyer, Matthias Eder, Constantinos Zamboglou and Ann-Christin Eder
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4033;
  • You have access
    PET imaging and Radiotherapy of Anti-Fibroblast activation protein antibody
    Mengxin Xu, Junyi Chen, Pu Zhang and Zhibo Liu
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4060;
  • You have access
    Radiolabeling of anti-CD20 ofatumumab with actinium-225 (225Ac) and therapeutic efficacy in a preclinical disseminated lymphoma model
    Mark Longtine, Kyuhwan Shim, Diane Abou, Mark Hoegger, Daniel Thorek and Richard Wahl
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4031;
  • You have access
    Noninvasive evaluation of EGFR expression of digestive tumors using the 99mTc-MAG3-Cet-F(ab')2 based SPECT/CT imaging
    Dai Shi, Yuan Cheng, Guobing Liu, Dengfeng Cheng and Hongcheng Shi
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4020;
  • You have access
    Theranostic gemcitabine-loaded collagenase conjugated liposome (GCL)
    Jee-eun Hwang, Miyeon Jeon, Wooseung Lee, Jeong-Seob Lee and Hyung-Jun Im
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4054;
  • You have access
    PSMA- versus FAP-RLT: Comparison of efficacy and post-treatment target expression in a double-positive mouse model of prostate cancer
    Marco Taddio, Firas Hikmat, Zuo Chunlai, Tamara Lotan, Colm Morissey, Giuseppe Carlucci, Huihui Ye, Caius Radu, Katharina Lueckerath, Johannes Czernin and Christine Mona
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4055;
  • You have access
    Leveraging PSMA-targeted radioligand therapy induced vulnerabilities by STING activation in prostate cancer
    Christine Mona, Marco Taddio, Khalid Rashid, Evan Abt, Ethan Rosser, Thuc Le, Katharina Lueckerath, Caius Radu and Johannes Czernin
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4040;
  • You have access
    Attempts to improve the pharmacokinetic Profile of Pharmacophore-modified 99mTc-N4-conjugated GRPR-targeted Compounds via Addition of a Ga-DOTA moiety
    Thomas Guenther, Sebastian Fischer, Angela Casini, Constantin Lapa and Wester Hans-Juergen
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 4057;

Pages

  • Previous
  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
SNMMI

© 2025 SNMMI

Powered by HighWire